vs
Side-by-side financial comparison of POTLATCHDELTIC CORP (PCH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
POTLATCHDELTIC CORP is the larger business by last-quarter revenue ($314.2M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). POTLATCHDELTIC CORP runs the higher net margin — 8.2% vs 1.6%, a 6.6% gap on every dollar of revenue. On growth, POTLATCHDELTIC CORP posted the faster year-over-year revenue change (23.1% vs 5.0%). Over the past eight quarters, POTLATCHDELTIC CORP's revenue compounded faster (11.1% CAGR vs -0.2%).
POTLATCHDELTIC CORPPCHEarnings & Financial Report
PotlatchDeltic Corporation is an American diversified forest products company based in Spokane, Washington.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PCH vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $314.2M | $177.4M |
| Net Profit | $25.9M | $2.9M |
| Gross Margin | 18.2% | — |
| Operating Margin | 11.2% | 3.9% |
| Net Margin | 8.2% | 1.6% |
| Revenue YoY | 23.1% | 5.0% |
| Net Profit YoY | 682.5% | — |
| EPS (diluted) | $0.33 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | $314.2M | $179.5M | ||
| Q2 25 | $275.0M | $181.1M | ||
| Q1 25 | $268.3M | $168.9M | ||
| Q4 24 | $258.1M | $187.3M | ||
| Q3 24 | $255.1M | $168.6M | ||
| Q2 24 | $320.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $25.9M | $5.4M | ||
| Q2 25 | $7.4M | $-4.8M | ||
| Q1 25 | $25.8M | $4.8M | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $3.3M | $-143.5M | ||
| Q2 24 | $13.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | 18.2% | 80.9% | ||
| Q2 25 | 13.0% | 77.4% | ||
| Q1 25 | 17.8% | 79.7% | ||
| Q4 24 | 13.4% | 78.7% | ||
| Q3 24 | 10.8% | 76.9% | ||
| Q2 24 | 11.9% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 11.2% | 3.5% | ||
| Q2 25 | 5.0% | 4.7% | ||
| Q1 25 | 10.3% | 1.2% | ||
| Q4 24 | 5.2% | 13.2% | ||
| Q3 24 | 2.8% | -82.8% | ||
| Q2 24 | 5.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 8.2% | 3.0% | ||
| Q2 25 | 2.7% | -2.7% | ||
| Q1 25 | 9.6% | 2.8% | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 1.3% | -85.1% | ||
| Q2 24 | 4.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | $0.33 | $0.12 | ||
| Q2 25 | $0.09 | $-0.11 | ||
| Q1 25 | $0.33 | $0.10 | ||
| Q4 24 | $0.07 | $0.38 | ||
| Q3 24 | $0.04 | $-3.11 | ||
| Q2 24 | $0.17 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $88.8M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $653.9M |
| Total Assets | $3.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | $88.8M | $246.3M | ||
| Q2 25 | $95.3M | $445.9M | ||
| Q1 25 | $147.5M | $493.6M | ||
| Q4 24 | $151.6M | $484.6M | ||
| Q3 24 | $161.1M | $453.8M | ||
| Q2 24 | $199.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $1.0B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | $1.9B | $727.2M | ||
| Q2 25 | $1.9B | $757.8M | ||
| Q1 25 | $2.0B | $798.5M | ||
| Q4 24 | $2.0B | $778.3M | ||
| Q3 24 | $2.1B | $749.6M | ||
| Q2 24 | $2.1B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $3.2B | $1.3B | ||
| Q2 25 | $3.2B | $1.5B | ||
| Q1 25 | $3.3B | $1.6B | ||
| Q4 24 | $3.3B | $1.6B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.51× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $65.7M | — |
| Free Cash FlowOCF − Capex | $50.1M | — |
| FCF MarginFCF / Revenue | 15.9% | — |
| Capex IntensityCapex / Revenue | 4.9% | — |
| Cash ConversionOCF / Net Profit | 2.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | $132.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $43.7M | ||
| Q3 25 | $65.7M | $60.8M | ||
| Q2 25 | $41.0M | $12.0M | ||
| Q1 25 | $49.1M | $35.5M | ||
| Q4 24 | $45.4M | $33.1M | ||
| Q3 24 | $26.5M | $53.9M | ||
| Q2 24 | $100.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | $50.1M | $57.0M | ||
| Q2 25 | $30.6M | $9.3M | ||
| Q1 25 | $26.3M | $26.9M | ||
| Q4 24 | $25.4M | $31.0M | ||
| Q3 24 | $-8.2M | $49.8M | ||
| Q2 24 | $72.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | 15.9% | 31.7% | ||
| Q2 25 | 11.1% | 5.1% | ||
| Q1 25 | 9.8% | 15.9% | ||
| Q4 24 | 9.9% | 16.6% | ||
| Q3 24 | -3.2% | 29.6% | ||
| Q2 24 | 22.6% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | 4.9% | 2.2% | ||
| Q2 25 | 3.8% | 1.5% | ||
| Q1 25 | 8.5% | 5.1% | ||
| Q4 24 | 7.7% | 1.1% | ||
| Q3 24 | 13.6% | 2.4% | ||
| Q2 24 | 8.8% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.54× | 11.20× | ||
| Q2 25 | 5.58× | — | ||
| Q1 25 | 1.90× | 7.37× | ||
| Q4 24 | 8.74× | — | ||
| Q3 24 | 7.99× | — | ||
| Q2 24 | 7.35× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCH
| Lumber | $131.8M | 42% |
| Timberlands | $52.5M | 17% |
| Rural Real Estate | $51.3M | 16% |
| Residuals And Panels | $34.0M | 11% |
| Pulpwood | $16.7M | 5% |
| Development Real Estate | $14.6M | 5% |
| Other | $8.1M | 3% |
| Other Products | $5.2M | 2% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
